Citation Tools

Download PDFPDF
Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

Download to a citation manager

Cite this article as:
García Trevijano Cabetas M, Escario-Gómez M, González-Del Valle L, et al
Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?